Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
News|Articles|October 10, 2017
Desiccant Tablets Measure Moisture in Blister Pack Testing
Clariant’s Tri-Sorb Desiccant Tablets are designed for USP moisture testing of blister packs.
Tri-Sorb molecular sieve desiccant tablets from Clariant’s Healthcare Packaging business unit are specifically designed for pharmaceutical and nutraceutical packagers who are conducting moisture-permeation testing of unit-dose blister packaging as prescribed in the United States Pharmacopeia (USP) standard USP <671>. The desiccant tablets are designed for placement into blister headspaces, either singly or in multiples, in lieu of the actual drug product, where they are used to test and verify the moisture vapor transmission rate (MTVR) of blister packaging according to the USP standard.
The tablets are packaged in quantities suitable for laboratory testing applications, with 320-350 tablets, depending on tablet size, in each resealable barrier pouch. To ensure product integrity and moisture adsorption capacity, Tri-Sorb desiccant tablets are not repackaged by a third party, but packaged directly on-site as part of the manufacturing process.
Tri-Sorb tablets are made from 4A molecular sieve and are available in three sizes: 0.125 g, 0.25 g, and 0.37 g. Similar Tri-Sorb tablets are also widely used in the packaging of medical devices and rapid diagnostic tests, where they protect functionality, accuracy, and shelf life from being compromised by moisture.
Source:
Related to this article
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights
5